stopOverflowHandler
New therapeutic target for the treatment of Alzheimer’s disease
Principal investigator : Dulce PAPY-GARCIA

CONTEXT

Alzheimer’s disease (AD) is the most common cause of dementia and affects around 27 millions people in the world. This disease is characterized by a progressive neurodegeneration leading to complete dependance of the patient, and has a major economic and societal impact in developed countries.

One of the hallmarks of AD is the accumulation of misfolded A-beta and Tau proteins. Tau is a microtubule-associated protein that stabilizes the neuron cytoskeleton, and especially axons. Upon AD onset, biochemical changes will induce Tau hyper-phosphorylation that cause its dissociation from microtubules leading to their disintegration, with consequence the neuronal loss-of-function.

 


¡Para continuar la lectura conéctese ! au lieu de ¡Para leer la consecuencia, conectarse!
 
< Anterior   Siguiente >
 
 

indentificación






Direct Access
+33 1 40 51 00 90
29/01/13 : FIST SA : un nouveau Directeur Général

Olivier DANIEL vient d’être nommé Directeur Général de la société FIST SA (France Innovation Scientifique ...
Details ...



04/02/13 : Une technologie valorisée par FIST SA dans la presse (Muller)  Lupus : des essais cliniques confirment l'efficacité du peptide P140/LupuzorTM Details ...



21/03/2013 : CNRS INNOVATION la lettre n°2  La seconde édition de CNRS INNOVATION la lettre est parue le 19 Mars 2013 Lien Details ...



 
   
viagra 100mg